Spectranetics研制治疗表浅股动脉完全堵塞的导管

  
 
一种新型涡轮导管被设计用于治疗表浅股动脉(SFA)的完全堵塞。该导管已经获得美国食品药品管理局的许可。

这种2.5涡轮导管是CLiRpath系列的最新产品，是具有知识产权的受激准分子激光导管，直径从0.9mm～2.5mm不等。这种新激光具有几种增强的设计功能。包括激光纤维数量增加，能够多产生30%的能量，穿透速度快了60%，能够消融较大的SFA和膝后动脉；持续的发射激光队列能够使得手术时间缩短并减少放射暴露；水解被膜能够产生更平滑地推进至紧密的病变处，能够较为容易地跨越动脉分杈处。

许多患外周血管疾病和严重肢体缺血的患者出现完全堵塞，标准引导钢丝不能穿过病变处，因此缺乏有效的治疗选择--或者进行旁路手术或者截肢--这几乎是不可避免的。CLiRpath为这些患者提供了截肢以外的治疗选择。

“我们最领先之处是穿越了关键的肢体缺血市场，通过增强我们现有产品，侧重于SFA和膝盖以下部位血管的完全堵塞这一难题，同时扩大我们治疗外周血管疾病领域，使用导管将会在下肢上部或者表浅股动脉产生更大的内腔。”Spectranetics(Colorado Springs, CO, USA)公司总裁兼首席执行官John G. Schulte如此评价，正是该公司研制开发了这种新型涡轮导管。

Turbo Catheter Treats Total Occlusions
 
A new turbo catheter is designed to treat total occlusions in the superficial femoral artery (SFA). The catheter has been cleared by the U.S. Food and Drug Administration (FDA).

The 2.5 turbo catheter is the latest in the CLiRpath line of proprietary excimer laser catheters, ranging in diameter from 0.9 mm to 2.5 mm. This new laser features several design enhancements. These include an increased number of laser fibers, which create 30% more energy and 60% faster penetration rate to ablate larger lumens in the SFA and popliteal arteries; a continuous lasing train that will enable shorter procedure times and reduce radiation exposure; and a hydrophilic coating to allow for smoother advancement through tight lesions and an easier transition over the aortic bifurcation.

Many patients suffering from peripheral vascular disease and critical limb ischemia have total occlusions that cannot be crossed with standard guide wires, and have so few treatment options that surgery--either bypass or limb amputation--is nearly inevitable. CLiRpath provides an alternative to amputation for these patients.

“Our top priority is to further penetrate the critical limb ischemia market through enhancements to our current products focusing on long total occlusions in the SFA and below-the-knee applications, and also to expand our presence in the treatment of peripheral vascular disease with catheters that will generate larger lumens in the upper leg or the superficial femoral artery,” said John G. Schulte, president and CEO of Spectranetics (Colorado Springs, CO, USA), which developed the new turbo catheter.